Key result
Late-stage metastatic cancer is linked to heightened platelet hyperreactivity and spontaneous aggregation versus healthy controls.
Why the study?
Do patients with late-stage metastatic cancer display increased platelet hyperreactivity compared to healthy controls?
Population
13 patients with histologically proven incurable stage VI metastatic cancer and 10 healthy controls.
Design
Case-control
Authors
Loading...
May inform thrombosis risk in metastatic cancer; hypothesis-generating, requires prospective trials before therapeutic consideration.
Case-Control (n=23)
No
Do patients with late-stage metastatic cancer display increased platelet hyperreactivity compared to healthy controls?
p-value: p=≤0.001
Patients with metastatic cancer exhibit global platelet hyperreactivity, providing a potential mechanistic explanation for their increased risk of cancer-associated thrombosis.
Cooke et al. (2013) conducted a case-control in Late-stage metastatic cancer (n=23). Late-stage metastatic cancer vs. Healthy controls was evaluated on Spontaneous platelet aggregation (SPA) and agonist-induced platelet aggregation (p=≤0.001). Patients with late-stage metastatic cancer displayed global platelet hyperreactivity, including significantly increased spontaneous platelet aggregation (P ≤ 0.001) compared to healthy controls.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: